MYOTONACHOL (bethanechol chloride) by Teva is clinical pharmacology bethanechol chloride acts principally by producing the effects of stimulation of the parasympathetic nervous system. Approved for acute postoperative, postpartum nonobstructive (functional) urinary retention, for neurogenic atony of the urinary bladder with retention. First approved in 1975.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Bethanechol chloride acts principally by producing the effects of stimulation of the parasympathetic nervous system. It increases the tone of the detrusor urinae muscle, usually producing a contraction sufficiently strong to initiate micturition and empty the bladder. It…
Worked on MYOTONACHOL at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.